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the war of nature, from famine and death, the most exalted object
which we are capable of conceiving, namely, the production of the
higher animals, directly follows. There is grandeur in this view of
life, with its several powers, having been originally breathed into a
few forms or into one; and that, while this planet has gone cycling
on according to the fixed law of gravity, from so simple a beginning
endless formsmost beautiful andmostwonderful have been, and are
being, evolved.3
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COMMENTARIES
MEDICINE AND LAW
Science, Politics, and Values
The Politicization of Professional Practice Guidelines
John D. Kraemer, JD, MPH
Lawrence O. Gostin, JD
THE INFECTIOUSDISEASES SOCIETY OFAMERICA (IDSA)issued updated clinical practice guidelines in 2006for the diagnosis and treatment of Lyme disease.1Within days, the Connecticut attorney general
launched an investigation, alleging IDSA had violated state
antitrust law by recommending against the use of long-
term antibiotics to treat “chronic Lyme disease (CLD),” a
label applied by advocates to a variety of nonspecific symp-
toms for which frequently no evidence suggests the etio-
logic agent of Lyme disease is responsible. The IDSA was
forced to settle the claim to avoid exorbitant litigation costs,
even though the society’s guidelines were based on sound
science. The case exemplifies the politicization of health
policy, with elected officials advocating for health policies
against the weight of scientific evidence.
The Antitrust Investigation of IDSA
Although untreated or inadequately treated Lyme disease
can progress to cause neurological complications and ar-
thritis, there is no evidence the disease has a chronic form
(except perhaps as sequelae) in the absence of objective clini-
cal or serological evidence of active infection.2 Neverthe-
less, some patient groups and a small minority of physi-
cians contend Borrelia burgdorferi, the causative agent of
Lyme disease, commonly persists in patients after standard
antibiotic treatments. They maintain that a constellation of
nonspecific symptoms such as fatigue, myalgia, head-
aches, and chest pain are evidence of chronic infection, and
that standard diagnostics are inaccurate.3 Furthermore, some
recommend using long-term, high-dose antibiotics—
frequently administered intravenously—to treat patientswith
nonspecific symptoms and no objective evidence of infec-
tion.3
The IDSA treatment guidelines strongly disagreed and in-
stead labeled the constellation of symptoms “post-Lyme syn-
drome”—either sequelae without ongoing infection or un-
related to B burgdorferi. The guidelines state, “There is no
convincing biologic evidence for the existence of sympto-
matic chronic B burgdorferi infection among patients after
receipt of recommended treatment regimens for Lyme dis-
ease. Antibiotic therapy has not proven to be useful and is
not recommended for patients with chronic (6 months)
subjective symptoms after recommended treatment regi-
mens for Lyme disease.”1 The IDSA guidelines also re-
jected the use of a variety of alternative diagnostic tests
deemed unvalidated by the Centers for Disease Control and
Prevention (CDC) and US Food and Drug Administration.
IDSA’s guidelines were based on the biological implau-
sibility of B burgdorferi persistence after proper treatment
in the absence of objective indications of treatment failure;
the high background rates of the subjective symptoms of-
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ten attributed to chronic Lyme infection; and the absence
of benefit from, and the serious adverse effects of, long-
term treatment. TheCDC4 andNational Institutes of Health5
concurred in the judgment that long-term antibiotic use is
not justified: “despite extensive study, no clear evidence has
emerged to support the contention that CLD results from a
past or persistent Lyme disease infection.”5 American Acad-
emy of Neurology treatment guidelines for Lyme disease af-
fecting the nervous system reached the same conclusion.6
The International Lyme and Associated Diseases Society
(ILADS), a CLD advocacy group, immediately protested and
asserted the superiority of its alternative guidelines,3 which
others have suggested were based on substandard review
methods.7 Shortly after, Connecticut Attorney General
Richard Blumenthal launched an investigation of IDSA’s
guideline writing process, alleging it violated state anti-
trust laws by excluding differing viewpoints from its guide-
line creation process and including members who had fi-
nancial interests in, or ties to, Lyme diagnostic and treatment
makers.8 IDSA did disclose its panelmembers’ potential con-
flicts of interest in its published guidelines, even though there
is no evidence that any conflicts altered the guidelines’ con-
tent.Meanwhile, the committee that created the ILADSguide-
lines included the president of a company that manufac-
tures an alternative Lymedisease diagnostic test9 andmultiple
physicians whose practices are listed with a CLD advocacy
group’s patient referral service10—but ILADS did not dis-
close the conflicts in its guideline document.3
Antitrust laws are designed to ensure legitimate commer-
cial competition andprotect against predatory corporate prac-
tices due to inappropriate restraints on trade. Professional or-
ganizations, such as IDSA, can violate antitrust laws if their
standard-setting is an unreasonable attempt to advance their
members’ economic interests by suppressing competition.11
Applying the antitrust “rule of reason,” a challengermust show
that the professional organization both possesses substan-
tial market power and that the anticompetitive effects of its
standards outweigh patient benefits.12 Even assuming IDSA
wielded sufficientmarketpower through itsnonbindingguide-
lines to meet the first part (which is questionable consider-
ing that insurers and clinicians can independently choose
which treatments to cover and prescribe), the second part of
the rule of reason cannot bemet because IDSAguidelines sub-
stantially advanced patients’ interests.
The courts should defer to professional medical associa-
tions when standards are set on the basis of valid science
aimed at protecting patient health or safety. A precisely on-
point federal case (though one that does not bind Connecti-
cut courts interpreting the state antitrust law) upheld the
American Academy of Ophthalmology guidelines attach-
ing the label “experimental” to radial keratotomy, a surgi-
cal procedure for correcting nearsightedness.13 “Antitrust
law is about consumers’ welfare,” said the court, so ulti-
mately professional guidelines are a “medical not a legal ques-
tion.”13 That truism should decide antitrust cases, so that
when a professional organization bases itswork on theweight
of science there can be no improper restraint of trade.
After spending more than a quarter of a million dollars
on legal expenses, IDSA agreed to settle with the attorney
general (without admitting any fault), assenting to an om-
budsmen-reviewed panel to assess the 2006 guidelines.14
While it is unlikely IDSA’s guidelines will change due to the
investigation, the daunting potential for litigation by those
unhappywith the outcomes of treatment guidelinesmaywell
chill the willingness of medical associations tomake appro-
priate scientific evaluations of controversial topics—a de-
velopment that would significantly threaten patient care and
increase medical costs.
Science, Values, and Politics
At the heart of this controversy is the conflict between the
positive nature of science and the normative function of value
systems and political thought. Science is, and can only be,
descriptive and explanatory.Whether a scientific finding is
judged to be accurate is dependent on the quality and rigor
of the methods used and whether that finding is replicable.
The scientific process is not democratic—no amount of de-
sire for different results can establish them—and inconsis-
tent findings create true controversy only when their meth-
ods are of comparable validity.
At the same time, the sciences cannot be normative. They
can establish context and a factual base for normative dis-
course, but scientific findings cannot entail any particular
normative conclusion without reference to outside sys-
tems of thought. Science, for example, cannot resolve the
never-ending debate over abortion in theUnited States.Medi-
cal science can describe the maternal health risks of preg-
nancy, elucidate fetal development, and establish risks of
birth defects and complications. Nothing, however, inher-
ently follows from any of these; rather, policy makers must
look outside science, to moral, religious, ethical, and legal
norms—eg,when aggregated cells becomehuman life orwhat
the relationship between citizens and their government
should be. Medical science can, and should, inform these
discussions, and in a vibrant and healthy society, such value
questions will be vigorously debated.
However, all too often, the normative and positive blend
into one another. Positive assertions are presented in a nor-
mative light—for example, that the cost of treating a con-
dition surpasses a benchmark of cost-effectiveness, hence
it should not be used. This really consists of 3 separate as-
sertions: the cost of treatment equals a particular amount
(a positive claim); treatments costing more than a certain
amount are not cost-effective; and cost-effectiveness should
guide the allocation of health care resources. All these claims
may be justifiable, but only the first can be established
through scientific methods.
The converse—when normative views are passed off as
positive assertions—is even more problematic, such as the
well-documented issue of abortion and breast cancer in the
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Bush administration.Multiple adequately powered andwell-
designed and analyzed studies investigated the putative as-
sociation between abortion and breast cancer and found no
evidence of its existence. However, from 2002 to 2003, in-
formation was placed on the National Cancer InstituteWeb
site suggesting a link between abortion and breast cancer,
based largely on older epidemiologic studies that failed to
sufficiently control for recall bias.15
The Connecticut attorney general’s action against IDSA
falls into this latter category. The CLD advocacy commu-
nity understandably seeks answers for the symptoms attrib-
uted to Lyme disease. But when high-quality research re-
peatedly was inconsistent with the group’s hypotheses, the
community should have sought other answers. Instead,many
advocacy organizations—and the attorney general—
insisted (against the weight of evidence) on a link between
the symptoms and chronic infection and continued to call
for long-term antibiotic treatments. Even this was perhaps
defensible—after all, medical studies cannot prove the non-
existence of a phenomenon—althoughphysicians in theCLD
community should treat their patients based on the best-
available evidence. But when political leaders using the force
of law sued IDSA for its appropriate scientific conclusions
that differed with the results they desired, they abused the
public good.
A wall of separation is needed between science, norms,
and politics. Science should inform normative discussions
and provide the evidentiary base for political choices. Like-
wise, values will always be important in deciding how sci-
ence is applied for human benefit. But neither should be per-
mitted to distort the other—limits on the outer boundaries
of what questions each can answer must be respected when
making public policy. Medical science, and the health of pa-
tients who depend on it, are too important to be subjected
to political ideologies.
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